自体CIK细胞对晚期不同阶段肿瘤患者免疫状态和生活质量的影响

摘要

目的 探讨自体细胞因子诱导的杀伤细胞(CIK)治疗晚期恶性肿瘤患者,对其免疫状态和生活质量的影响.方法 选取2013年2月至2016年3月合肥市第一人民医院血液肿瘤科收治的42例晚期肿瘤患者,按照预计生存期分为A组(预计生存期＜3个月)20例、B组(预计生存期≥3个月)22例,检测治疗前后A、B组患者外周血T细胞亚群的变化.观察治疗前后A、B组患者免疫功能的变化,生活质量改善情况及治疗相关不良反应.结果 CIK细胞治疗后,A组患者CD3T细胞水平较治疗前降低(P＜0.05);B组治疗后CD3+、CD4+和CD4+/CD8+水平较治疗前明显升高(P＜0.05),CD8+T淋巴细胞亚群水平较治疗前降低(P＜0.05).A、B两组患者治疗后KPS评分分别较治疗前均有提高,其中A组差异无统计学意义(P＞0.05),而B组差异有统计学意义(P＜0.05).42例患者在输注CIK过程中未出现明显不良反应.结论 CIK细胞回输安全、副作用小,自体CIK细胞治疗可提高晚期恶性肿瘤患者的免疫功能,改善其生活质量,但应尽早进行.%Objective To observe the efficacy of autogenous cytokine-induced killer (CIK) cells on the life quality and immune status in the patients with advanced cancer.Methods From Feb 2013 to Mar 2016,42 cases of patients with advanced cancer ever treated ir our hospital were enrolled in the study,and according to their expected survival time,they were divided into group A of less than 3 months 2C cases and group B of equal to or more than 3 months 22 cases.All patients in the two groups were tested the levels of peripheral blood T lymphocyte subsets before and after the self-CIK cells treatment,and the changes of immune function and life quality in group A and group B before and after treatment,together with related adverse reactions,were observed.Results After treatment,the levels of CD3+ T lymphocytes in group A and CD8+ T lymphocytes in group B decreased significantly than before (all P ＜ 0.05),but the levels of CD3+,CD4+ and CD4+ /CD8+ in group B increased significantly (P ＜ 0.05).The KPS scores after treatment in both groups were higher than those before treatment,but in group B the difference was significant (P ＜ 0.05),and in group A it was not (P ＞ 0.05).No remarkable adverse reaction was found during the infusion of self-CIK cells in these 42 patients.Conclusion The therapy of self-CIK cells transfusion is safe and low-toxic for the patients with advanced cancer,and might improve their immune function and life quality,but it should be carried out early.